Quantitative analysis of the IgG and IgG subclass immune responses to chromosomal *Pseudomonas aeruginosa* \(\beta\)-lactamase in serum from patients with cystic fibrosis by western blotting and laser scanning densitometry

Tine D Petersen, Oana Ciofu, Tacjana Pressler, Birgit Giwercman, Svend S Pedersen, Niels Hoiby

Abstract

**Background** — Antibodies against chromosomal \(\beta\)-lactamase of *Pseudomonas aeruginosa* (afab) are markers of the development of resistance of *P aeruginosa* to \(\beta\)-lactam antibiotics in patients with cystic fibrosis and chronic lung infection. The role of these antibodies in patients with chronic lung infection with *P aeruginosa* was further investigated by correlating the afab IgG subclasses with pulmonary function in patients with cystic fibrosis.

**Methods** — Immunoglobulin G (IgG) and IgG subclass afab were investigated by western blotting and quantified by laser scanning densitometry. A longitudinal study on 43 consecutive patients with cystic fibrosis who developed chronic lung infection with *P aeruginosa* was performed.

**Results** — IgG subclass afab appeared in all patients with chronic infection with *P aeruginosa*. Eleven years after the onset of infection all the patients had IgG4, 79% had IgG1, 56% IgG2, and only 16% of the patients had IgG1, afab. The IgG1 and IgG4 afab appeared first, and more than 50% of the patients were IgG1 and IgG4 afab-positive within 2–3 years of the onset of infection, but IgG1 positivity only appeared after seven years and IgG4 remained absent from most of the patients. The median afab levels increased during chronic infection: 100-fold for IgG1, 22-fold for IgG2, and 45-fold for IgG4. A 16-fold increase in the IgG1 afab levels was detected in the six patients who developed IgG1 afab. In the first four years of the chronic infection the afab titres were higher in patients with good lung function than in those with poor lung function.

**Conclusions** — The association of a weak IgG1 and a strong IgG4, afab response suggests that the contribution of afab antibodies to lung diseases mediated by immune complexes might be less important than other antipseudomonal antibodies. A beneficial neutralising effect of the afab antibodies on the antibiotic destroying enzymes may be an additional factor.

(Thorax 1996;51:733–738)

Keywords: cystic fibrosis, IgG, antibodies, *Pseudomonas aeruginosa*, \(\beta\)-lactamase.

In most cystic fibrosis centres the occurrence of *Pseudomonas aeruginosa* strains resistant to \(\beta\)-lactam antibiotics is a common problem in patients with chronic *P aeruginosa* lung infection.\(^1\)\(^2\) The most important resistance mechanism consists of large amounts of chromosomal \(\beta\)-lactamase produced by stably derepressed *P aeruginosa* strains, as shown previously in our population with cystic fibrosis.\(^3\)\(^4\) These strains are selected in vivo by antibiotic pressure.\(^5\)\(^6\) Besides this mechanism, the permeability barrier and the drug efflux mechanisms are also involved in the development of resistance to \(\beta\)-lactam antibiotics.\(^7\)\(^8\) While these two mechanisms mainly explain the intrinsic resistance of *P aeruginosa* to a wide array of antimicrobial agents including \(\beta\)-lactams,\(^9\) the production of chromosomal \(\beta\)-lactamase is mainly responsible for the high levels of resistance to \(\beta\)-lactam antibiotics encountered in strains collected from patients who have been intensively treated with ureidopenicillins and third-generation cephalosporins.\(^8\)

High levels of \(\beta\)-lactamase activity have been found in the sputum of patients with cystic fibrosis,\(^10\) which could lead to inactivation of \(\beta\)-lactam antibiotics. Antibodies against the chromosomal *P aeruginosa* \(\beta\)-lactamase (afab) have been detected in the serum and sputum of patients with cystic fibrosis and chronic lung infection with *P aeruginosa*.\(^11\)

The presence in the serum of both \(\beta\)-lactamase activity and afab has led to several hypotheses on their clinical significance. One theory emphasises the potential protective role of the afab antibodies by inhibiting the extracellular \(\beta\)-lactamase and thus improving the effect of the \(\beta\)-lactam antibiotics. However, another hypothesis emphasises the possible destructive role of these antibodies by participating with the extracellular \(\beta\)-lactamase in immune complexes which could play an important part in the pathogenesis of airway injury in cystic fibrosis by mediating type III hypersensitivity inflammatory reactions.\(^12\)

We have previously shown that afab antibodies are markers of the development of re-
sistance of \( P \) \textit{aeruginosa} in patients with cystic fibrosis and chronic bronchopulmonary infection.\textsuperscript{13} In order to clarify some of the questions raised on the clinical significance of afab antibodies we have conducted a more detailed investigation of the immune response to chromosomal \( \beta \)-lactamase.

The IgG subclasses have different abilities to participate in phagocytosis and complement activation.\textsuperscript{14} We therefore investigated the development of different IgG afab subclasses during the course of chronic infection with \( P \) \textit{aeruginosa}. An inverse correlation has been described between the IgG and IgG, antibodies to \( P \) \textit{aeruginosa} cell sonicate, alginate, outer membrane proteins, lipopolysaccharide (LPS) and lung function,\textsuperscript{15-18} so we also investigated whether there was a correlation between lung function and the IgG subclass pattern of afab.

**Methods**

**PATIENTS WITH CYSTIC FIBROSIS**

The diagnosis of cystic fibrosis was based on accepted criteria including genotype, abnormal sweat electrolyte levels in repeated tests, and exocrine pancreatic insufficiency. After diagnosis, the patients with cystic fibrosis were monitored monthly at the Danish Cystic Fibrosis Centre at Rigshospitalet. Data on the clinical condition and sputum bacteriology have been recorded prospectively since 1970. The following definitions were used to describe the patients with regard to \( P \) \textit{aeruginosa} infection: non-infected (CF – P) were patients without growth of \( P \) \textit{aeruginosa} in their sputum at the regular monthly examinations and with no increase in serum antibodies to \( P \) \textit{aeruginosa} (less than two precipitin bands against \( P \) \textit{aeruginosa} sonicated antigen); and chronically infected (CF + P) were patients in whom \( P \) \textit{aeruginosa} was present in the sputum at each monthly examination for more than six months or who had more than two precipitin bands.\textsuperscript{19}

Pulmonary function (forced vital capacity (FVC) and forced expiratory volume in one second (FEV\(_1\)) were determined at each monthly visit using an electronic spirometer (Spirotron, Dräger, Denmark). All values were expressed as percentage of the expected values according to height and sex. The individual values in this study were the mean of all results in one year during the observation period. Poor lung function was defined as an FEV\(_1\) value of <40% of the predicted value and good lung function as an FEV\(_1\) value of >70% predicted.

For the purpose of the present longitudinal study, multiple serum samples (8–14 samples/patient) were obtained at intervals of six months to one year from 43 consecutive CF + P and 11 age matched CF – P patients. The age of the patients at the onset of the chronic infection was evenly distributed between 0-8 and 29 years (median 10 years). The CF + P samples covered the pre-infection period and the early and late stages of chronic \( P \) \textit{aeruginosa} infection. Seven of the 43 CF + P patients had chronic infection with a sensitive strain, a resistant strain being only intermittently isolated. From the 36 patients chronically infected with a resistant strain, nine had poor lung function and nine had good lung function. These were matched for age at the onset of the chronic infection and intensity of the treatment with \( \beta \)-lactam antibiotics. The rest of the patients with CF – P had intermediate lung function. Since 1976 all the chronically infected patients with cystic fibrosis have been admitted to the centre every third month for a two week intravenous course of antipseudomonal antibiotics consisting of a combination of tobramycin and a \( \beta \)-lactam antibiotic.\textsuperscript{20}

**HEALTHY CONTROLS**

In order to establish normal values for the assay, serum samples from 39 consecutive healthy controls with no history of \( P \) \textit{aeruginosa} infection were investigated. The median age (range) for 20 children was 11–7 years (1–18–7) and for 19 adults was 27 years (18–53 years).

\( \beta \)-LACTAMASE AND MURINE MONOCLONAL ANTIBODIES

\( \beta \)-lactamase from \( P \) \textit{aeruginosa} was produced and purified as reported previously.\textsuperscript{13} Monoclonal antibodies were made and antibodies from clone 3G2A11F7/07–1993 were used for the experiments.\textsuperscript{11,13}

**SDS-PAGE AND IMMUNOBLOTTING**

All the serum samples were tested by immunoblotting. Purified \( \beta \)-lactamase was subjected to sodium dodecylsulphate-polyacrylamide gel electrophoresis (SDS–PAGE) on a 12-5% acrylamide running gel and 5% stacking gel.\textsuperscript{21} Samples were denatured before loading by heating to 100°C for five minutes with an equal quantity of sample buffer containing 2-5% w/v SDS. The loading of \( \beta \)-lactamase was 0.84 \( \mu \)g protein/cm\(^2\) of the top surface. The antigen was transferred from polyacrylamide gels to nitrocellulose paper (0-45 \( \mu \)m BA 85 cellulose nitrate, Schleicher and Schuell, Dassel, Germany).\textsuperscript{22} Blotting was carried out on a semi-dry blot apparatus (JKA-Biortem) at 0.8 A/cm\(^2\) for 90 minutes. The protein transfer on the nitrocellulose paper after blotting was checked by overnight Coomassie staining of the gel (Coomassie blue (Sigma), 0-1% w/v in methanol 50% v/v acetic acid 10%) and compared with a similar gel which had not been blotted. The unbound sites from the nitrocellulose paper were blocked by 30 minutes incubation with Tris-HCl0.05 M, NaCl0.1 M, 0-05% NaN\(_3\) (TBS) containing 2% Tween 20. Two mm wide strips of the nitrocellulose paper were then incubated overnight at 4°C with different serum samples.

Serum samples from patients diluted 1:20 and a standard sample (a reference pool of 10 cystic fibrosis serum samples selected from the late phase of infection with high antibody titres) diluted 1:1000 were used for incubating blots of the pure \( \beta \)-lactamase. All dilutions were carried out in TBS/0-5% Tween 20. The
IgG subclass antibodies against chromosomal P aeruginosa \( \beta \)-lactamase

**Figure 1** Immunoblots of \( \beta \)-lactamase incubated with serum samples collected during 1978–88 from a chronically infected patient with cystic fibrosis (lanes 1–8), with monoclonal antibody (lane 9), and with standard serum (lane 10).

nitrocellulose paper strips were washed thoroughly with the same buffer and incubated further for one hour at room temperature with peroxidase conjugated rabbit antihuman gamma chain specific antibody (P214, Dako, Copenhagen, Denmark) diluted 1:500. The colour was developed by DONS-TMB (dihydrinoctylamine sulphosuccinate-tetramethyl benzidine; Merck).

All IgG a\(\tilde{a}\)b positive samples in the screening assay were tested for the presence of different IgG subclasses by immunoblotting. The following dilutions were used for the tested serum samples: 1:200 for IgG1, IgG2, and IgG3, and 1:50 for IgG4 subclass determination. The standard sample was diluted as previously (1:1000 in TBS buffer). Peroxidase conjugated IgG subclass monoclonal antibodies (anti-IgG1: HP-6069, anti-IgG2: HP-6014, anti-IgG3: HP-6025, all diluted 1:500, and anti-IgG4: HP-6050 diluted 1:250; CLB, Amsterdam, The Netherlands) were used as secondary antibodies. In both assays controls with the murine monoclonal antibody against \( \beta \)-lactamase were run using rabbit anti-mouse IgG antibodies (P260 Dako, Copenhagen, Denmark) diluted 1:100 as secondary antibodies.

After incubation with the different secondary antibodies the nitrocellulose paper was thoroughly washed with TBS and the reactive sites were visualised with DONS-TMB. The antigen concentration, serum and antibody dilutions, and incubation times were chosen after preliminary investigations with serial dilutions of serum samples from chronically infected patients.

The immunoblots were allowed to dry at room temperature and, in order to avoid colour fading, they were scanned immediately using a Hewlett-Packard ScanJet IIP to measure the antibody response. The laser scan shows the antigen-antibody reactions as a number of peaks and the area under the curve corresponds to the levels of antibodies. The \( \beta \)-lactamase preparation was pure showing only a single band (peak) on the immunoblot with polyclonal (patient) and monoclonal serum samples (fig 1). This band corresponded to the band on a silver stained SDS-PAGE gel and to the reaction with nitrocefin (a chromogenic \( \beta \)-lactamase substrate). Isoelectrofocusing showed a band with \( pI=8.2 \). Coomassie blue staining of the gel after blotting showed that there was complete transfer of the protein onto the nitrocellulose paper.

The area under the curve was analysed in a Compaq/Deskpro 466/33m, LTE, FASTART using the CREAM 4.1 program (Kem-En-Tech, Copenhagen, Denmark). The results were expressed as units and calculated by dividing the intensity of the band obtained with the tested serum by the intensity of the band obtained with the standard serum multiplied by 10, an arbitrary value given to the standard serum for all four subclasses.

**SPECIFICITY OF THE IMMUNOBLOTTING ASSAY**

The assay was antigen specific as demonstrated by absorption experiments. Incubation of serum samples with increasing amounts of \( \beta \)-lactamase led to the detection of decreasing amounts of IgG antibodies on the immunoblots. A reduction from 35% to 90% in the a\(\tilde{a}\)b detection was obtained by incubating the serum with increasing concentrations of \( \beta \)-lactamase from 0.2 to 1.2 \( \mu \)g/ml serum. Preabsorption with LPS and outer membrane proteins had no influence on the a\(\tilde{a}\)b titres.

The mouse monoclonal antibodies to human IgG, 4 were of World Health Organisation reference quality and displayed the desired specificity in immunoassays.

**SENSITIVITY OF THE IMMUNOBLOTTING ASSAY**

Doubling dilutions of the \( \beta \)-lactamase from an initial loading of 20 \( \mu \)g were separated on SDS-PAGE, transferred to nitrocellulose paper, and allowed to react with patient serum samples diluted 1:20. The lowest amount of antigen which could be detected was 1 \( \mu \)g/strip, equivalent to 0.2 ng protein/mm.

To determine the lower level of detection of serum antibodies, doubling dilutions of the standard serum were allowed to react with 0.2 cm strips of nitrocellulose paper loaded with \( \beta \)-lactamase equivalent to 0.2 ng protein/mm. At each dilution the density of the bands decreased until, at a dilution of 1:150 000, no band was visible. The highest dilution at which a reaction could be seen was 1:75 000.

The sensitivity of this immunoblotting assay, expressed as the ratio between the serum quantity and the area on which the serum reacts, was 0.006 \( \mu \)l/cm\(^2\). By comparison, the sensitivity of the immunoblotting assay to detect antibodies against \( P \) aeruginosa sonicate (standard antigen) was 0.014 \( \mu \)g/cm\(^2\), which illustrates the high sensitivity of our assay.

Isolation of serum IgG, from six patients with IgG, a\(\tilde{a}\)b and three patients without IgG,

Downloaded from http://thorax.bmj.com/ on June 24, 2017 - Published by group.bmj.com
aβab as detected by immunoblotting was performed. The serum samples were delipidated (with 0-4% dextrane sulphate and calcium chloride) and applied to a protein A-Sepharose CL-4B, cyanogen bromide activated column (Sigma, St Louis, Missouri, USA) (binding buffer 3-3 M NaCl, 0-15 M glycine, pH 8-5; elution buffer 0-1 M citrate buffer, pH 2-7; neutralising buffer 1 M Tris, pH 9). The unbound fraction containing human IgG, and the elution fraction containing the other subclasses were analysed for the presence of aβab by immunoblotting. No differences were detected between the IgG, aβab levels in the whole serum and the IgG fraction. This excluded the possibility of a false negative IgG, result caused by a competitive inhibition by the other IgG subclasses.

**ANTIBODY DETERMINATION BY ELISA**

Measurements of IgG aβab and of antibodies against *P aeruginosa* sonicate by ELISA in the same group of patients have been published previously.1,2,5

**REPRODUCIBILITY OF THE IMMUNOBLOTTING ASSAY**

The intraday and day-to-day variation were determined after blotted strips were allowed to react with 10 serum samples of low (n = 4), medium (n = 3), and high (n = 4) antibody concentration. Variation was calculated using the formula SD = \sqrt{\sum d^2}/2n where SD is the standard deviation, d is the sum of squared differences of double determinations of the same sample, and n is the number of samples. The intraday variations of the antibody titres of IgG, were 13%, 5%, 12%, and 18%, and the day-to-day variations were 14%, 11%, 17%, and 11%, respectively.

**STATISTICAL ANALYSIS**

The Mann–Whitney test for unpaired data and the Spearman rank correlation coefficient were used to test the statistical significance of the differences between the groups of patients.

**Results**

**IgG and IgG SUBCLASS ANTIBODIES TO P. AERUGINOSA CHROMOSOMAL β-LACTAMASE**

IgG aβab antibodies were present in all CF-P patients who were chronically infected with a strain resistant to β-lactam antibiotics and in three patients with intermittent colonisation with a resistant strain. These antibodies could not be detected by immunoblotting in any of the samples from either the control group of healthy children or from the non-infected (CF-P) patients, nor in samples from four of the seven patients chronically infected with a sensitive strain.

The IgG positive samples were subsequently assayed for β-lactamase specific subclass antibodies. The aβab response was most prevalent for subclasses IgG, and IgG, being present in 100% and 79% of the patients, respectively, after 11 years of chronic infection. IgG, and IgG, subclasses were detected in 56% and 16% of the patients, respectively. These results are shown in the table.

The IgG and IgG, aβab appeared first, with more than 50% of the patients being IgG, and IgG, positive within 2–3 years after the onset of the chronic infection. It took seven years to develop IgG, antibodies in 50% of the patients and IgG antibodies developed in only 16% of the patients.

During the 11 year period of the study the median IgG antibody levels increased 22-fold, IgG, 100-fold, IgG, 22-fold, IgG, 45-fold, and IgG, median remained zero (fig 2). IgG, aβab were present in only six patients with cystic fibrosis, and all of them became positive in the first three years following the start of the chronic infection. The levels in this group of patients increased 16-fold during the 11 year period of the study.

The IgG aβab levels measured by immunoblotting showed a statistically significant correlation with aβab levels determined by ELISA from these patients (r >0-5, p <0-01).1

**aβab AND LUNG FUNCTION IN PATIENTS WITH CYSTIC FIBROSIS**

Figure 3 shows the development of IgG aβab antibodies in nine patients with good lung function and in nine patients with poor lung function, all of them chronically harbouring a resistant strain.

The aβab antibodies appeared in the group of patients with good lung function 18–24 months...
IgG subclass antibodies against chromosomal P aeruginosa β-lactamase

with cystic fibrosis. The strong association with the IgG3 subclass may be explained by the strong complement activating ability of IgG3 antibodies which may lead to tissue damage mediated by polymorphonuclear leucocytes. In contrast with the immune response to other P aeruginosa antigens, a pronounced IgG3 aβab response was found. The IgG4 subclass is exceptional in several respects. IgG4 antibodies to various antigens appear to be functionally monovalent and thus produce small, non-precipitating immune complexes while, at the same time, they are unable to fix complement.

It has also been proposed that high levels of IgG4 antibodies could be a marker for hyperimmunoreactivity. Their presence could be harmless or beneficial by suppressing the immunopathology caused by other antibodies via antagonistic or competitive mechanisms. The low IgG3 aβab and high IgG4 levels in serum samples of patients with cystic fibrosis suggest that the anti-β-lactamase antibodies probably do not make an important contribution to the immune complex mediated lung tissue damage. This is in contrast to IgG2 and IgG4 antibodies to other P aeruginosa antigens. The association between a high IgG4 immune response and good lung function in patients with cystic fibrosis has also been found for antibodies against protein H of the P aeruginosa outer membrane.

Another important and surprising observation of our study is the early and high aβab response in patients with good lung function compared with those with poor lung function. This is in direct contrast to that previously observed for antibodies against P aeruginosa sonicate antigen where high levels were correlated significantly with poor lung function. This suggests that patients with an early production of aβab are probably able to inhibit the extracellular β-lactamase activity. Inhibition of β-lactamase activity in biofilms by monoclonal antibodies has been shown by our group (unpublished results). The inhibition of β-lactamase by aβab would lead to the protection of the β-lactam antibiotic from enzymatic hydrolysis which may result in more efficacious anti-pseudomonal treatment. The good lung function in the group of patients with high aβab levels may therefore be a consequence of in vivo protection by β-lactamase antibodies. In vitro experiments investigating this hypothesis are in progress at our laboratory.

In conclusion, the aβab antibodies appear to have a protective role in patients who develop them early in the course of the chronic infection with P aeruginosa, by inhibiting the extracellular β-lactamase activity.

The prevalence of IgG1 and IgG4 suggests a minor role for the aβab subclass of antibodies in the immune complex mediated injury of the airway of patients with cystic fibrosis.

Further studies are required to clarify the function and activity of the aβab antibodies in patients with cystic fibrosis and chronic infection of the lung with P aeruginosa.

This study was supported by a grant from the Danish Cystic Fibrosis Association.

---

Figure 3 Development of IgG aβab and aαb P aeruginosa (aAb) antibodies during chronic infection with resistant P aeruginosa strains in nine patients with poor lung function and nine with good lung function.


Quantitative analysis of the IgG and IgG subclass immune responses to chromosomal Pseudomonas aeruginosa beta-lactamase in serum from patients with cystic fibrosis by western blotting and laser scanning densitometry.

T. D. Petersen, O. Ciofu, T. Pressler, B. Giwercman, S. S. Pedersen and N. Høiby

*Thorax* 1996 51: 733-738
doi: 10.1136/thx.51.7.733

Updated information and services can be found at:
http://thorax.bmj.com/content/51/7/733

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/